FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912004757> ?p ?o ?g. }

• W2912004757 endingPage "229" @default.
• W2912004757 startingPage "223" @default.
• W2912004757 abstract "Background Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B). Methods Both trials consisted of carboplatin AUC 6 day 1, and paclitaxel 60 mg/m2 on days 1,8, 15 of a 21-day cycle; in Trial B, patients received IV bevacizumab 15 mg/kg every cycle starting cycle 2. Chemotherapy was administered IV for cycle 1 and then IP for all subsequent cycles. Primary objectives included safety and tolerability, pathologic CR rate (Trial A), and the rate of completion of IP cycles of therapy (Trial B). Progression-free (PFS), overall survival (OS), and pharmacokinetic analysis were secondary endpoints. Results 81 patients were treated on both trials (n = 40 and 41 in trials A and B, respectively). Median age for trials A and B was 59 (range, 36–76) and 55 (range, 19–69) years, respectively. 68% and 85% of patients, respectively for A and B, completed at least 4 cycles of treatment in both trials. Treatment with bevacizumab resulted in higher rates of grade 3 fatigue (37 versus 33%) and grade 3–4 diarrhea (22 versus 8%). Median PFS was 23.5 (95%CI 16.2–35.3) and 25 (95%CI 16.4–42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0–79.7) months, respectively for Trial A and B. Conclusions Weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity with and without concommittant bevacizumab in these 2 trials." @default.
• W2912004757 created "2019-02-21" @default.
• W2912004757 creator A5000311133 @default.
• W2912004757 creator A5028288310 @default.
• W2912004757 creator A5030257115 @default.
• W2912004757 creator A5033018791 @default.
• W2912004757 creator A5033501805 @default.
• W2912004757 creator A5040266917 @default.
• W2912004757 creator A5058249824 @default.
• W2912004757 creator A5068473904 @default.
• W2912004757 creator A5078818153 @default.
• W2912004757 creator A5081561534 @default.
• W2912004757 creator A5087242712 @default.
• W2912004757 creator A5089509810 @default.
• W2912004757 creator A5089955620 @default.
• W2912004757 creator A5090143508 @default.
• W2912004757 date "2019-05-01" @default.
• W2912004757 modified "2023-10-02" @default.
• W2912004757 title "Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin" @default.
• W2912004757 cites W1969942245 @default.
• W2912004757 cites W1999457401 @default.
• W2912004757 cites W2008868978 @default.
• W2912004757 cites W2087073539 @default.
• W2912004757 cites W2097265582 @default.
• W2912004757 cites W2099373382 @default.
• W2912004757 cites W2102306754 @default.
• W2912004757 cites W2113122060 @default.
• W2912004757 cites W2128868545 @default.
• W2912004757 cites W2130806638 @default.
• W2912004757 cites W2130941707 @default.
• W2912004757 cites W2135947389 @default.
• W2912004757 cites W2154175915 @default.
• W2912004757 cites W2170552969 @default.
• W2912004757 cites W2329492928 @default.
• W2912004757 cites W4247449815 @default.
• W2912004757 doi "https://doi.org/10.1016/j.ygyno.2019.02.004" @default.
• W2912004757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30765148" @default.
• W2912004757 hasPublicationYear "2019" @default.
• W2912004757 type Work @default.
• W2912004757 sameAs 2912004757 @default.
• W2912004757 citedByCount "5" @default.
• W2912004757 countsByYear W29120047572020 @default.
• W2912004757 countsByYear W29120047572023 @default.
• W2912004757 crossrefType "journal-article" @default.
• W2912004757 hasAuthorship W2912004757A5000311133 @default.
• W2912004757 hasAuthorship W2912004757A5028288310 @default.
• W2912004757 hasAuthorship W2912004757A5030257115 @default.
• W2912004757 hasAuthorship W2912004757A5033018791 @default.
• W2912004757 hasAuthorship W2912004757A5033501805 @default.
• W2912004757 hasAuthorship W2912004757A5040266917 @default.
• W2912004757 hasAuthorship W2912004757A5058249824 @default.
• W2912004757 hasAuthorship W2912004757A5068473904 @default.
• W2912004757 hasAuthorship W2912004757A5078818153 @default.
• W2912004757 hasAuthorship W2912004757A5081561534 @default.
• W2912004757 hasAuthorship W2912004757A5087242712 @default.
• W2912004757 hasAuthorship W2912004757A5089509810 @default.
• W2912004757 hasAuthorship W2912004757A5089955620 @default.
• W2912004757 hasAuthorship W2912004757A5090143508 @default.
• W2912004757 hasConcept C126322002 @default.
• W2912004757 hasConcept C126894567 @default.
• W2912004757 hasConcept C141071460 @default.
• W2912004757 hasConcept C143998085 @default.
• W2912004757 hasConcept C197934379 @default.
• W2912004757 hasConcept C2776694085 @default.
• W2912004757 hasConcept C2777802072 @default.
• W2912004757 hasConcept C2778239845 @default.
• W2912004757 hasConcept C2778375690 @default.
• W2912004757 hasConcept C2781413609 @default.
• W2912004757 hasConcept C2781451048 @default.
• W2912004757 hasConcept C535046627 @default.
• W2912004757 hasConcept C71924100 @default.
• W2912004757 hasConcept C90924648 @default.
• W2912004757 hasConceptScore W2912004757C126322002 @default.
• W2912004757 hasConceptScore W2912004757C126894567 @default.
• W2912004757 hasConceptScore W2912004757C141071460 @default.
• W2912004757 hasConceptScore W2912004757C143998085 @default.
• W2912004757 hasConceptScore W2912004757C197934379 @default.
• W2912004757 hasConceptScore W2912004757C2776694085 @default.
• W2912004757 hasConceptScore W2912004757C2777802072 @default.
• W2912004757 hasConceptScore W2912004757C2778239845 @default.
• W2912004757 hasConceptScore W2912004757C2778375690 @default.
• W2912004757 hasConceptScore W2912004757C2781413609 @default.
• W2912004757 hasConceptScore W2912004757C2781451048 @default.
• W2912004757 hasConceptScore W2912004757C535046627 @default.
• W2912004757 hasConceptScore W2912004757C71924100 @default.
• W2912004757 hasConceptScore W2912004757C90924648 @default.
• W2912004757 hasFunder F4320310274 @default.
• W2912004757 hasFunder F4320332193 @default.
• W2912004757 hasIssue "2" @default.
• W2912004757 hasLocation W29120047571 @default.
• W2912004757 hasLocation W29120047572 @default.
• W2912004757 hasOpenAccess W2912004757 @default.
• W2912004757 hasPrimaryLocation W29120047571 @default.
• W2912004757 hasRelatedWork W1970429237 @default.
• W2912004757 hasRelatedWork W2088563918 @default.
• W2912004757 hasRelatedWork W2163214112 @default.
• W2912004757 hasRelatedWork W2169335753 @default.
• W2912004757 hasRelatedWork W2395106973 @default.

• next